Adaptive Biotechnologies (ADPT) Metrics: History & Chart

Adaptive Biotechnologies Corporation(ADPT)

Biotechnology · Seattle, WA

$30.22+0.38 (+1.28%)

Delayed quote: Oct 6, 2026, 9:30 AM EDT

About Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For confirming past COVID-19 infections, Adaptive provides T-Detect COVID. Additionally, clonoSEQ functions as a critical clinical diagnostic tool, enabling the detection and continuous monitoring of minimal residual disease in individuals with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia; it is also available as a CLIA-validated laboratory-developed test for other lymphoid cancers. Another specialized offering, immunoSEQ T-MAP COVID, aids vaccine developers and researchers in quantifying T-cell immune responses to vaccines. Beyond its current product lineup, Adaptive Biotechnologies actively develops a pipeline of clinical products and services designed for the diagnosis, monitoring, and treatment of conditions such as cancer, autoimmune disorders, and infectious diseases. Its solutions cater to life science research, clinical diagnostics, and drug discovery applications. The company has established key strategic collaborations: one with Genentech, Inc., for the joint development, manufacturing, and commercialization of neoantigen-directed T-cell therapies aimed at treating various cancers; and another with Microsoft Corporation, dedicated to creating sophisticated diagnostic tests capable of identifying multiple diseases early from a single blood sample.

Seattle, WA

624 employees

www.adaptivebiotech.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Chad Robins

View full financials

Third-Party DCF Estimate (FMP)	N/A
Price Gap vs Third-Party Estimate	N/A

7D Total Return	+4.67%
30D Total Return	+22.90%
YTD Total Return	+83.74%
1Y Total Return	+107.51%
3Y Total Return	+529.54%
5Y Total Return	-8.54%
10Y Total Return	N/A
15Y Total Return	N/A
20Y Total Return	N/A

2026	+83.74%
2025	+170.67%
2024	+22.45%
2023	-35.86%
2022	-72.77%
2021	-52.55%
2020

CAGR TTM	+106.79%
CAGR 3Y	+84.62%
CAGR 5Y	-1.77%
CAGR 10Y	N/A
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	N/A
PE Ratio Avg TTM	N/A
PE Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

All Metrics

ADPT Valuation Metrics

ADPT Stock Price Metrics

ADPT Dividend Metrics

ADPT Growth Rate Metrics

ADPT Discounted Cash Flow Metrics

ADPT Returns By Period

ADPT Yearly Returns

ADPT Average Annual Returns By Period (CAGR)

ADPT Revenue Metrics

ADPT PE Ratio Metrics

ADPT PS Ratio Metrics

ADPT PB Ratio Metrics

ADPT Price to Free Cash Flow Ratio Metrics

ADPT Debt to Equity Ratio Metrics

ADPT PEG Ratio Metrics

ADPT FCF Yield

ADPT Earnings Yield

ADPT EBITDA Yield

ADPT OCF Yield

ADPT EV/EBIT Ratio Metrics

ADPT EV/EBITDA Ratio Metrics

ADPT EV/Assets Ratio Metrics

ADPT EV/Sales Ratio Metrics

ADPT Current Ratio Metrics

ADPT Quick Ratio Metrics

ADPT ROIC Metrics

ADPT Return on Assets Metrics

ADPT Return on Equity Metrics

ADPT Net Profit Margin Metrics

ADPT Gross Profit Margin Metrics

ADPT Tax Rate Metrics

PS Ratio	15.27
PS Ratio Avg TTM	10.54
PS Ratio Avg 3Y	6.93
Current VS TTM Avg	+44.91%
Current VS 3Y Avg	+120.24%
Current VS 5Y Avg	+112.29%

PB Ratio	32.93
PB Ratio Avg TTM	12.60
PB Ratio Avg 3Y	6.68
Current VS TTM Avg	+161.42%
Current VS 3Y Avg	+392.66%
Current VS 5Y Avg	+538.73%

PFCF Ratio	24.38
PFCF Ratio Avg TTM	17.85
PFCF Ratio Avg 3Y	17.85
Current VS TTM Avg	+36.59%
Current VS 3Y Avg	+36.59%
Current VS 5Y Avg	+36.59%

Debt/Equity Ratio	2.87
Debt/Equity Ratio Avg TTM	1.20
Debt/Equity Ratio Avg 3Y	0.38
Current VS TTM Avg	+139.90%
Current VS 3Y Avg	+659.92%
Current VS 5Y Avg	+853.77%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	4.10%
FCF Yield Avg TTM	5.61%
FCF Yield Avg 3Y	5.61%
Current VS TTM Avg	-26.97%
Current VS 3Y Avg	-26.97%
Current VS 5Y Avg	-26.97%

Earnings Yield	N/A
Earnings Yield Avg TTM	N/A
Earnings Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	N/A
Ev/Ebit Ratio Avg TTM	N/A
Ev/Ebit Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebitda Ratio	N/A
Ev/Ebitda Ratio Avg TTM	N/A
Ev/Ebitda Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Assets Ratio	7.72
Ev/Assets Ratio Avg TTM	5.67
Ev/Assets Ratio Avg 3Y	3.05
Current VS TTM Avg	+36.25%
Current VS 3Y Avg	+153.36%
Current VS 5Y Avg	+201.38%

Ev/Sales Ratio	16.06
Ev/Sales Ratio Avg TTM	10.97
Ev/Sales Ratio Avg 3Y	7.20
Current VS TTM Avg	+46.36%
Current VS 3Y Avg	+123.11%
Current VS 5Y Avg	+119.03%

Current Ratio	4.79
Current Ratio Avg TTM	3.54
Current Ratio Avg 3Y	3.84
Current VS TTM Avg	+35.41%
Current VS 3Y Avg	+25.01%
Current VS 5Y Avg	+16.51%

Quick Ratio	4.68
Quick Ratio Avg TTM	3.43
Quick Ratio Avg 3Y	3.70
Current VS TTM Avg	+36.40%
Current VS 3Y Avg	+26.38%
Current VS 5Y Avg	+17.85%

ROIC	(6.67%)
ROIC Avg 3Y	(28.97%)
ROIC Avg 5Y	(28.14%)
Current VS 3Y Avg	+76.98%
Current VS 5Y Avg	+76.30%
Current VS 10Y Avg	+71.20%

ROA	(9.97%)
ROA Avg TTM	(3.21%)
ROA Avg 3Y	(5.88%)
Current VS TTM Avg	-210.98%
Current VS 3Y Avg	-69.69%
Current VS 5Y Avg	-68.32%

ROE	(44.68%)
ROE Avg TTM	(40.25%)
ROE Avg 3Y	(60.28%)
Current VS TTM Avg	-11.01%
Current VS 3Y Avg	+25.88%
Current VS 5Y Avg	+14.13%

Net Profit Margin	(20.73%)
Net Profit Margin Avg TTM	(27.23%)
Net Profit Margin Avg 3Y	(71.97%)
Current VS TTM Avg	+23.88%
Current VS 3Y Avg	+71.20%
Current VS 5Y Avg	+77.90%

Gross Profit Margin	75.44%
Gross Pft Margin Avg TTM	73.90%
Gross Pft Margin Avg 3Y	64.99%
Current VS TTM Avg	+2.08%
Current VS 3Y Avg	+16.07%
Current VS 5Y Avg	+14.40%

Tax Rate	0.00%
Tax Rate Avg 3Y	N/A
Tax Rate Avg 5Y	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A
Current VS 10Y Avg	N/A